Clinical trial
Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal…
NCT00363831 · The University of Hong Kong, Other · Unknown status
Key facts
| NCT number | NCT00363831 |
|---|---|
| Title | Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma |
| Official title | A Multi-center Phase II Trial of Capecitabine in Combination With Oxaliplatin (Xelox) as First Line Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma (NPC) |
| Lead sponsor | The University of Hong Kong, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Nasopharyngeal Neoplasms |
| Intervention type | Drug |
| Interventions | Oxaliplatin |
| Enrollment | 42 |
| Start date | Jul 1, 2006 |
| Primary completion | Dec 1, 2009 |
| First posted | Aug 15, 2006 |
| Last update posted | Jul 28, 2010 |
| Countries | Hong Kong |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: